Entrar/Registro  
HOME SPANISH
 
Cirujano General
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Cirujano General >Year 2000, Issue 4


Sigler ML
Prevention of venous thromboembolic disease: Results from a survey among general surgeons.
Cir Gen 2000; 22 (4)

Language: Español
References: 30
Page: 342-346
PDF: 4. Kb.


Full text




ABSTRACT

Introduction: Venous thromboembolic disease is important as it can course asymptomatically or cause death. The last years have witnessed a change in interests regarding risk assessment, diagnostic methods and treatment of this disease.
Objective: To know which diagnostic methods and preventive measures are being used by the general surgeon.
Material and methods: A survey was performed among 300 attendants to the National Congress of General Surgery. The survey consisted of 10 questions regarding their working place, whether their hospitals have teaching activities, what diagnostic procedures are used and which preventive measures are being implemented to reduce thromboembolic disease.
Results: We received 277 (92%) answers; 51% work in some public institution, 22% in the private praxis, and 45% in both, private and institutional, praxes. Teaching activities are performed in 87% of the hospitals. Diagnostic measures are distributed as follows: 49% phlebography, 26% color duplex Doppler, 8% scintigraphy, 3% dimmer D, and all these resources are used by 11%. Preventive measures are: elastic bandages, 66%; elastic stockings, 34%; and intermittent compression devices, 6.7%; drugs are used by 84%, and none by 16%. Low molecular weight heparin is used by 56%, standard heparin by 37%, and other products by 6%. Drugs are used during the preoperative period by 64% and not by 36%. Half of the surveyed would like to have more knowledge regarding prevention and treatment of the disease.
Conclusion: It is recommended to use non-invasive methods for the diagnosis of thromboembolic disease. Dissemination of knowledge on recent advances that offer better diagnostic methods and treatment to the surgical patients must be continued.


Key words: Thrombosis, thromboembolism, pulmonary embolism, primary prevention.


REFERENCIAS

  1. Clagett GP, Anderson FA Jr, Geerts W, Heit JA, Knudson M, Lieberman JR et al. Prevention of venous thromboembolism. Chest 1998; 114(5 Suppl): 531S-60S.

  2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115: 591-5.

  3. Bratzler DW, Raskob GE, Murray CK, Bumpus LJ, Piatt DS. Underuse of venous thromboembolism prophylaxis for general surgery patients. Physician practices in the community hospital setting. Arch Intern Med 1998; 158: 1909-12.

  4. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O´Fallon WM, Melton LJ III, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Int Med 1998; 158: 585-93.

  5. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-anallysis. Am Surg 1988; 208: 227-40.

  6. Fisher CG, Blachut PA, Salvain AJ , Meek RN, O´Brien PJ. Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomised study of compression alone versus no-prophylaxis. J Orthop Trauma 1995; 9: 1-7.

  7. Hull RD, Pineo GF. Prophylaxis of deep venous thrombosis and pulmonary embolism. Current recommendations. Med Clin North Am 1998; 82: 477-93.

  8. Comerota AJ, Chouhan V, Harada RN, Sun L, Hosking J, Veermansunemi R, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 1997; 226: 306-13; discussion 313-4.

  9. Clagett GP, Anderson FA Jr, Levine MN, Salzman EW, Wheeler HB. Prevention of venous thromboembolism. Chest 1992; 102(4 Suppl): 391S-407S.

  10. Enoxacan Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomised multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099-103.

  11. Kakkar VV, Boeckl O, Boneu B, Bordenave L, Brehm OA, Brüke P, et al. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg 1997; 21: 2-9.

  12. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparine: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Arch Intern Med 1998; 158: 873-8.

  13. Caprini JA, Arcelus JI, Hoffman K, Mattern T, Laubach M, Size GP, et al. Prevention of venous thromboembolism in North America: results of a survey among general surgeons. J Vasc Surg 1994; 20: 751-8.

  14. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271: 1780-5.

  15. Nurmohamed MT, Verhaeghe R, Hass S, Iriarte JA, Vogel G, van Rij AM, et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995; 169: 567-71.

  16. Wiig JN, Solhaug JH, Bilberg T, Bjerkeset T, Edwin B, Gruner OP, et al. Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery: multicentre trials 20 mg and 40 mg enoxaparin versus dextran. Eur J Surg 1995; 161: 663-8.

  17. Bergmann J, Neuhart E. A multicenter randomised double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 1996; 76: 529-34.

  18. Bergqvist D, Benoni G, Björgell O, Fredin H, Hedlundh U, Nicolas S, et al. Low-molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335: 696-700.

  19. Geertz WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335: 701-7.

  20. Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractioned heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg 1997; 84: 750-9.

  21. Hass S, Flosbach CW. Prevention of postoperative thromboembolism with enoxaparin in general surgery: a German Multicenter Trial. Sem Thromb Hemost 1993; 19 (Suppl 1): 164-73.

  22. Lumpkin MM, FDA Alert. FDA public health advisory. Anesthesiology 1998; 88: 27A-8A.

  23. Greenfield LJ, Proctor MC, Rodriguez JL, Luchette FA, Cipole MD, Cho J. Post-trauma thromboembolism prophylaxis. J Trauma 1997; 42: 100-3.

  24. Headrick JR Jr, Barker DE, Pate LM, Horne K, Russell WL, Burns RP. The role of ultrasonography and inferior vena cava filter placement in high-risk trauma patients. Am Surg 1997; 63: 1-8.

  25. Rojas GA, Cervantes J, Ponte R, Ramírez S, García M. Interrupción de vena cava. Diez años de experiencia en el Hospital American British Cowdray. Cir Cirj 1999; 67: 17-21.

  26. Delgado Brambila HA, Cuervo González C, García Pinto G. Profilaxis de la trombosis venosa profunda asociada a la cirugía de la cadera y de la rodilla: una combinación de heparina estándar y dehidroergotamina. Rev Mex Ortop Traumatol 1993; 7: 199-202.

  27. Delgado Brambila HA, García Pinto G. Profilaxis de la trombosis venosa profunda asociada a la cirugía de la cadera y de la rodilla. Uso de una heparina de bajo peso molecular: enoxaparina. Rev Mex Ortop Traumatol 1993; 7: 203-6.

  28. Cruz-Vásquez FG, Vásquez J, Delgado HA, Velasco A. Profilaxis de la trombosis venosa profunda con enoxaparina en pacientes con fracturas mayores de las extremidades inferiores. Rev Mex Ortop Traumatol 1998; 12: 391-8.

  29. Castañón-González JA, Gallegos-Pérez H, Miranda-Ruiz R, Vásquez de Anda G, Colmenero-Zubiate S. Heparina de bajo peso molecular como profilaxis antitrombótica en pacientes graves y en estado crítico con alto riesgo de hemorragia y/o trombosis. Med Int Mex 1996; 12: 73-6.

  30. Morales-Polanco MR, Sigler-Morales L, Meillón-García LA, Romero-Hernández T, Blanco-Benavides R. Valoración de los efectos indeseables de una heparina de bajo peso molecular, durante la profilaxia de enfermedad tromboembólica en pacientes de cirugía abdominal. Gac Med Mex 1997; 133: 541-6.






>Journals >Cirujano General >Year 2000, Issue 4
 

· Journal Index 
· Links 






       
Copyright 2019